Emerging areas of research with prospective clinical translation include RON inhibition in conjunction with existing cytotoxic anti-cancer therapies to promote sensitization and immunogenicity and to target CSC populations that drive cancer metastasis and recurrence. This evidence concerns the gene MST1R and cancer.